Volanesorsen for treating familial chylomicronaemia syndrome
KEYWORDS: volanesorsen, committee, clinical, treatment, levels, patients, people, fcs, company, approach, model, risk, noted, erg, utility

experts, NHS England and a review by the evidence review group (ERG). See the committee papers for full details of the evidence. In forming the recommendations, the committee took into account the full range of factors that might affect its decision, including in particular the nature of the condition, the clinical effectiveness, value for money and the impact beyond direct health benefits. Nature of the condition Burden of disease 4.1 The patient and clinical experts explained how the condition affects all aspects of the lives of people with familial chylomicronaemia syndrome (FCS), and their families and carers. It has a significant effect on a person's independence, and their ability to work and have a social life. People with FCS live in constant fear of having a life-threatening attack of acute pancreatitis (AP) and recurrent hospital admissions. This can be depressing for them, and worrying for their families and carers. Unpredictable hospital admissions can disrupt both a patient's and carer's work. Also, the children of people with FCS often have to be carers for their parents and siblings. The committee also heard that people with FCS are often unable to participate in usual family activities because of strict dietary restrictions. This
